Intellia Therapeutics Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Intellia Therapeutics (NTLA) PT Raised to $39 at Raymond James
November 5, 2020 12:52 PM ESTRaymond James analyst Steven Seedhouse raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $39.00 (from $27.00) while maintaining a Outperform rating.
... MoreIntellia Therapeutics (NTLA) Tops Q3 EPS by 12c, Revenues Beat
November 5, 2020 8:13 AM ESTIntellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($0.47), $0.12 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $22.22 million versus the consensus estimate of $15.58 million.
We are very pleased with the recent regulatory... More
